Lingohr Asset Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

Lingohr Asset Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-2,395	Closed	-$254K	–	98
2025 Q2	$254K	Sell	2,395 -37,288	-94%	-$4.05M	0.46%	72
2025 Q1	$4.93M	Buy	39,683 +36,805	+1,279%	+$4.8M	1.23%	41
2024 Q4	$354K	Buy	+2,878	New	+$339K	0.73%	58
2022 Q1	–	Sell	-2,935	Closed	-$376K	–	100
2021 Q4	$376K	Hold	2,935	–	–	0.94%	76
2021 Q3	$382K	Hold	2,935	–	–	1.02%	72
2021 Q2	$521K	Sell	2,935 -1,100	-27%	-$191K	1.31%	22
2021 Q1	$663K	Buy	4,035 +1,900	+89%	+$313K	1.66%	5
2020 Q4	$352K	Hold	2,135	–	–	1.02%	61
2020 Q3	$304K	Sell	2,135 -965	-31%	-$120K	1.08%	17
2020 Q2	$336K	Hold	3,100	–	–	1.36%	23
2020 Q1	$309K	Sell	3,100 -4,756	-61%	-$615K	1.65%	14
2019 Q4	$1.17M	Buy	7,856 +600	+8%	+$81.7K	1.13%	15
2019 Q3	$930K	Buy	7,256 +3,100	+75%	+$416K	0.93%	34
2019 Q2	$592K	Buy	+4,156	New	+$559K	0.58%	84

Other funds holding JAZZ

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return

Lingohr Asset Management's JAZZ Position: Q3 2025 in Review

Lingohr Asset Management sold out of Jazz Pharmaceuticals (JAZZ) in Q3 2025, closing a stake of 2,395 shares — an estimated $254K sold.

Lingohr Asset Management first reported a position in JAZZ in Q2 2019 and held it in 14 quarters. The position peaked at $4.93M in Q1 2025. 502 funds tracked by Wall St. Rank hold JAZZ as of Q3 2025.

Lingohr Asset Management reported no remaining Jazz Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
Lingohr Asset Management sold 2,395 Jazz Pharmaceuticals shares in Q3 2025, an estimated $254K.
Lingohr Asset Management first reported a position in Jazz Pharmaceuticals in Q2 2019 and held it in 14 quarters.
Lingohr Asset Management's Jazz Pharmaceuticals position peaked at $4.93M in Q1 2025.
502 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q3 2025.

Based on Lingohr Asset Management's 13F filing for Q3 2025, filed 4 Nov 2025.